Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

FDA approves Randox ConcizuTrace ELISA CDx

July 2025—The Food and Drug Administration has approved the de novo application for Randox Laboratories’ first companion diagnostic, the Randox ConcizuTrace ELISA. The test, developed in collaboration with Novo Nordisk, is intended for the quantitative measurement of concizumab-mtci concentration in human 3.2 percent citrated plasma samples from patients with hemophilia A and B four weeks after the initiation of treatment. The measurement of the concentration is used for dose adjustment decision in accordance with the drug label.

Bio-Rad presents workshops, demos at ADLM 2025

July 2025—Bio-Rad Laboratories will present an array of clinical diagnostic-related offerings at this year’s Association for Diagnostics and Laboratory Medicine Clinical Lab Expo in Chicago, July 27–31. An industry workshop titled “From Waste to Wow: Optimizing Your Quality Control Workflow” is designed to provide attendees with strategies to streamline QC management across multihospital systems for systemwide efficiency, reduce waste streams in clinical chemistry, and recognize patient-based real-time QC to improve lab QC processes.

Study validates Ibex Breast solution

July 2025—Ibex Medical Analytics reports that a study conducted at Ohio State University Wexner Medical Center confirms that Ibex Breast, an AI-powered diagnostic support solution, significantly improves accuracy and efficiency in evaluating breast pathology cases (Tahir M, et al. Clin Breast Cancer. Published online March 26, 2025). The study analyzed 104 real-world breast biopsies, including invasive and microinvasive carcinomas, ductal carcinoma in situ, atypical lobular hyperplasia, and other benign lesions. Three breast pathologists independently reviewed each case digitally, with and without the support of Ibex Breast. Results demonstrated that when using AI, diagnostic accuracy improved from 97.1 percent to 100 percent, with previously missed precancerous lesions, such as lobular neoplasia and microcalcifications, correctly identified.

FDA clears Sysmex CN-6000 automated blood coag analyzer

July 2025—Sysmex America has received FDA clearance for its CN-6000 automated blood coagulation analyzer. The clearance also covers reagent products for prothrombin time seconds and PT INR (Dade Innovin), activated partial thromboplastin time (Dade Actin FSL), fibrinogen (Dade thrombin reagent), antithrombin (Innovance antithrombin), and D-dimer (Innovance D-dimer). Sysmex has also received Health Canada license for the CN-6000 as well as its CN-3000 automated blood coagulation analyzer.

BD launches FacsDiscover A8 cell analyzer

July 2025—BD announced the worldwide commercial launch of its FacsDiscover A8 cell analyzer. It features BD SpectralFX technology, which maximizes the number of colors that can be used in flow cytometry; BD CellView image technology, which enables high-speed fluorescent and label-free imaging of single cells; and intuitive software workflows that allow for effective management of large data sets. The analyzer pairs with BD FacsDiscover cell sorters and BD reagents.

Empire Genomics, BioDot to launch hematology FISH probe panels

July 2025—Empire Genomics and BioDot have partnered to launch a line of hematology-focused FISH probe panels and controls. The BDot Probe line is preoptimized, ready to use, and validated for performance on the BioDot CellWriter S platform. The initial release of the panels includes targeted solutions for FISH analysis of a range of hematologic malignancies, including multiple myeloma, myelodysplastic syndromes, chronic myelogenous leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, and other common hematologic disorders.

Agilent unveils InfinityLab Pro iQ series

July 2025—Agilent Technologies has launched its Agilent InfinityLab Pro iQ series of mass detectors for liquid chromatography. The series includes the InfinityLab Pro iQ and InfinityLab Pro iQ Plus and supports applications such as mass confirmation, impurity profiling, biomolecule characterization, trace contaminant detection, and compound purification. The Pro iQ system, with a mass range of m/z 2–1,600, is optimized for small molecule analysis, while the Pro iQ Plus system is engineered for high-end applications and has a mass range of m/z 2–3,000.

Pillar raises $34.5 million in funding

July 2025—Pillar Biosciences announced it has finalized $34.5 million in funding, which includes a strategic investment from Illumina and structured financing from Soleus Capital, as well as investments from existing investors. The proceeds will be leveraged to advance commercial activities, including infrastructure to support biopharma partnerships, and expand adoption of its distributable clinical testing kits.

Qiagen plans launch of three sample prep instruments

July 2025—Qiagen plans to launch three sample preparation instruments this year and next to expand its portfolio for automated sample preparation. QIAsymphony Connect, the next generation of the QIAsymphony, is progressing toward a phased launch to selected customers this year. The system, for in vitro diagnostic use, addresses pathogen nucleic acid extraction and other applications and can process up to 96 samples at a time. It features improved automation capabilities for sample tracking and new applications, higher yield for increase in assay sensitivity, and digital connectivity.

Labcorp launches MRD, liquid biopsy solutions

July 2025—Labcorp has expanded its precision oncology portfolio with its Labcorp Plasma Detect, to help assess the risk of disease recurrence in stage three colon cancer patients, and PGDx Elio Plasma Focus Dx, a kitted, pan-solid tumor liquid biopsy test authorized by the FDA to identify patients who may benefit from targeted treatments.

MARKETPLACE

TRENDING